Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354463 | 1.00 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL33377881 | 0.90 | CASP3 (0.54) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL10187000 | 0.88 | CASP3 (0.60) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL15223381 | 0.88 | CASP3 (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL13570148 | 0.88 | CASP3 (0.60) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL12261165 | 0.88 | CASP3 (0.57) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL14787492 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL12626898 | 0.87 | CASP3 (0.56) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL4552562 | 0.86 | CASP3 (0.71) | CASP3KMT2AEPHX2MDM4TP53 | |
| SCHEMBL31498750 | 0.86 | CASP3 (0.71) | CASP3KMT2AEPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090171068-A1 | Method of peptide synthesis | LONZA LTD. (CH) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171068-A1 | Method of peptide synthesis | PTMS, TMSB4X, TMSB10 | CASP3 4079/4885KMT2A 4431/4885EPHX2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.